EyePoint Pharmaceuticals, Inc. cash flow to debt ratio of -1.05K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

EyePoint Pharmaceuticals, Inc.'s free cash flow has decreased 86.82% from $-130.28M last year to $-243.39M, signaling decreasing performance

EyePoint Pharmaceuticals, Inc.'s debt to equity ratio is 0.09, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

EyePoint Pharmaceuticals, Inc.'s debt has increased relative to shareholder equity from 0.06 last year to 0.09 today, signaling weakened financials

EyePoint Pharmaceuticals, Inc. has negative EBITDA, making leverage ratio unreliable

EyePoint Pharmaceuticals, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

EyePoint Pharmaceuticals, Inc.'s profit margin has decreased (1.08K%) in the last year from -302.43% to -3.57K%, signaling decreasing performance

EyePoint Pharmaceuticals, Inc.'s short-term assets of $328.65M exceed its short-term liabilities of $37.02M

EyePoint Pharmaceuticals, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

EyePoint Pharmaceuticals, Inc.'s return on equity of -110.54%, is lower than 15.00%, indicating bad performance

EyePoint Pharmaceuticals, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

EyePoint Pharmaceuticals, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

EyePoint Pharmaceuticals, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

EyePoint Pharmaceuticals, Inc. has negative free cash flow, indicating cash burn

EyePoint Pharmaceuticals, Inc.'s yearly earnings has decreased 77.25% since last year from $-130.87M to $-231.96M, signaling decreasing performance

EyePoint Pharmaceuticals, Inc.'s yearly revenue has decreased -27.50% since last year from $43.27M to $31.37M, signaling decreasing performance

ROIC -112.37% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

EyePoint Pharmaceuticals, Inc.'s 3-year revenue CAGR of -8.83% is negative, indicating declining revenue over the past 3 years

EyePoint Pharmaceuticals, Inc. had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance

EyePoint Pharmaceuticals, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

EyePoint Pharmaceuticals, Inc. has insufficient data to evaluate this check.

EyePoint Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

EyePoint Pharmaceuticals, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

EyePoint Pharmaceuticals, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

EyePoint Pharmaceuticals, Inc. is overvalued relative to its fair value price of -6.92 based on Earnings Fair Value model

EyePoint Pharmaceuticals, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

EyePoint Pharmaceuticals, Inc. has a price-to-book ratio of 5.12x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

EyePoint Pharmaceuticals, Inc. has a price-to-sales ratio of 155.14x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue